



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

WILLIAMS *et al.*

Appl. No. 09/839,946

Filed: April 19, 2001

For: **PEG-Urate Oxidase Conjugates
and Use Thereof**

Confirmation No. 5256

Art Unit: 1652

Examiner: Saidha, T.

Atty. Docket: 2057.0090003/JAG/BJD

**Fifth Supplemental Information Disclosure Statement
and Fee Under 37 C.F.R. § 1.97(c)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fifth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fourth Supplemental Information Disclosure Statement filed on December 16, 2003, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not

be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Fifth Supplemental Information Disclosure Statement is being filed before the mailing of a final action on the merits or a Notice of Allowance, but after the mailing of a first action on the merits, in the captioned application. In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: Jan. 23, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2057.0090003/JAG/BJDAPPLICATION NO.
09/839,946APPLICANT
Williams et al.FILING DATE
April 19, 2001GROUP
1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	
	AS	<u>20</u>	Copy of commonly owned, co-pending U.S. Appl. No. 09/501,730, filed February 10, 2000 (unpublished).
	AT	<u>20</u>	"EC 1.7.3.3, urate oxidase," BRENDA Enzyme Database, available via internet at http://www.brenda.uni-koeln.de/ (cited by USPTO Examiner in related U.S. Appl. No. 09/501,730, filed February 10, 2000 (Doc. No. AS20), in Notice of Allowance dated January 13, 2004).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



COPY

Applicant: Williams *et al.*

Due Date: n/a

Art Unit: 1652

Examiner: Saidha, T.

Docket: 2057.0090003

Atty: JAG/BJD

Application No.: 09/839,946

Filed: April 19, 2001

For: PEG-Urate Oxidase Conjugates and Use Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover the appropriate fees;
3. PTO Fee Transmittal (PTO/SB/17);
4. Fifth Supplemental Information Disclosure Statement;
5. One page of Form PTO-1449 citing two documents;
6. A copy of each of the cited documents (AS20 and AT20); and
7. One (1) return postcard.



Please Date Stamp And Return To Our Courier

\\ODMA\MHODMA\SKGF_DC1\222427.1